Long-term in vivo expression of a broad and potent entry inhibitor could circumvent the need for a conventional vaccine for HIV-1. Adeno-associated virus (AAV) vectors can stably express HIV-1 broadly neutralizing antibodies (bNAbs)1,2. However, even the best bNAbs neutralize 10–50% of HIV-1 isolates inefficiently (80% inhibitory concentration (IC80) > 5 μg ml−1), suggesting that high concentrations of these antibodies would be necessary to achieve general protection3,4,5,6. Here we show that eCD4-Ig, a fusion of CD4-Ig with a small CCR5-mimetic sulfopeptide, binds avidly and cooperatively to the HIV-1 envelope glycoprotein (Env) and is more potent than the best bNAbs (geometric mean half-maximum inhibitory concentration (IC50) < 0.05 μg ml−1). Because eCD4-Ig binds only conserved regions of Env, it is also much broader than any bNAb. For example, eCD4-Ig efficiently neutralized 100% of a diverse panel of neutralization-resistant HIV-1, HIV-2 and simian immunodeficiency virus isolates, including a comprehensive set of isolates resistant to the CD4-binding site bNAbs VRC01, NIH45-46 and 3BNC117. Rhesus macaques inoculated with an AAV vector stably expressed 17–77 μg ml−1 of fully functional rhesus eCD4-Ig for more than 40 weeks, and these macaques were protected from several infectious challenges with SHIV-AD8. Rhesus eCD4-Ig was also markedly less immunogenic than rhesus forms of four well-characterized bNAbs. Our data suggest that AAV-delivered eCD4-Ig can function like an effective HIV-1 vaccine.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481, 81–84 (2011)

  2. 2.

    et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nature Med. 15, 901–906 (2009)

  3. 3.

    et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334, 1289–1293 (2011)

  4. 4.

    et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406–412 (2012)

  5. 5.

    et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466–470 (2011)

  6. 6.

    et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633–1637 (2011)

  7. 7.

    , , , & Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J. Virol. 76, 8769–8775 (2002)

  8. 8.

    et al. Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression. PLoS ONE 9, e112268 (2014)

  9. 9.

    et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280, 1949–1953 (1998)

  10. 10.

    et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317, 1930–1934 (2007)

  11. 11.

    , , , & sCD4–17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology 7, 11 (2010)

  12. 12.

    et al. Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children. J. Allergy Clin. Immunol. 119, 747–750 (2007)

  13. 13.

    et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 331, 78–81 (1988)

  14. 14.

    et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. 182, 326–329 (2000)

  15. 15.

    et al. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 5, e1000360 (2009)

  16. 16.

    , , , & The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure. J. Exp. Med. 176, 507–517 (1992)

  17. 17.

    et al. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J. Virol. 72, 6332–6338 (1998)

  18. 18.

    et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96, 667–676 (1999)

  19. 19.

    et al. A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J. Biol. Chem. 275, 33516–33521 (2000)

  20. 20.

    , , , & A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J. Biol. Chem. 281, 28529–28535 (2006)

  21. 21.

    et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114, 161–170 (2003)

  22. 22.

    et al. Enhanced recognition and neutralization of HIV-1 by antibody-derived CCR5-mimetic peptide variants. J. Virol. 86, 12417–12421 (2012)

  23. 23.

    , & ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617–621 (1996)

  24. 24.

    et al. A tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein. J. Virol. 85, 7563–7571 (2011)

  25. 25.

    et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439–1452 (2010)

  26. 26.

    et al. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J. Virol. 86, 12039–12052 (2012)

  27. 27.

    , , & A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection. J. Virol. 86, 12472–12483 (2012)

  28. 28.

    et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856–861 (2010)

  29. 29.

    et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 79, 8828–8834 (2005)

  30. 30.

    et al. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69, 6705–6711 (1995)

  31. 31.

    , , & Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206, 935–944 (1995)

  32. 32.

    , , , & Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J. Virol. 83, 8289–8292 (2009)

  33. 33.

    , & Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 82, 12585–12588 (2008)

  34. 34.

    et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896–1905 (2002)

  35. 35.

    et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74, 8358–8367 (2000)

  36. 36.

    , , , & Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72, 2855–2864 (1998)

  37. 37.

    et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J. Virol. 75, 1990–1995 (2001)

  38. 38.

    et al. The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1. J. Virol. 72, 6113–6118 (1998)

  39. 39.

    et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135–1148 (1996)

  40. 40.

    et al. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J. Virol. 72, 1160–1164 (1998)

  41. 41.

    , , , & Direct expression and validation of phage-selected peptide variants in mammalian cells. J. Biol. Chem. 288, 18803–18810 (2013)

  42. 42.

    et al. Human immunodeficiency virus type 1 Env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108–10125 (2005)

  43. 43.

    et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIVmac251 challenge. PLoS Pathog. 8, e1002890 (2012)

  44. 44.

    et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73, 2343–2349 (1999)

  45. 45.

    et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277–280 (2013)

  46. 46.

    et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nature Biotechnol. 28, 839–847 (2010)

  47. 47.

    et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol. 43, 2709–2717 (2005)

  48. 48.

    et al. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 8, e1002797 (2012)

  49. 49.

    , , & Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure 3, 265–278 (1995)

  50. 50.

    et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl Acad. Sci. USA 101, 2706–2711 (2004)

Download references


This project was supported by National Institutes of Health (NIH) grants R01 AI091476 and R01 AI080324 (M.F.), P01 AI100263 (G.G., R.C.D., M.F.), RR000168 (M.R.G., L.M.K., D.T.E., R.C.D., M.F.), R01 AI058715 (B.H.H.), by the Intramural Research program of the Vaccine Research Center, NIAID, NIH (J.G., B.Z., P.D.K.), and by federal funds from the National Cancer Institute, NIH under contract no. HHSN261200800001E. The authors would like to thank H. Choe and M. Martin for critical advice.

Author information

Author notes

    • Matthew R. Gardner
    •  & Lisa M. Kattenhorn

    These authors contributed equally to this work.


  1. Department of Infectious Diseases, The Scripps Research Institute, Jupiter, Florida 33458, USA

    • Matthew R. Gardner
    • , Hema R. Kondur
    • , Tatyana Dorfman
    • , Charles C. Bailey
    • , Christoph H. Fellinger
    • , Vinita R. Joshi
    • , Brian D. Quinlan
    •  & Michael Farzan
  2. Department of Comparative Pathology, Harvard Medical School, New England Primate Research Center, Southborough, Massachusetts 01772, USA

    • Lisa M. Kattenhorn
    • , Jessica J. Chiang
    • , Michael D. Alpert
    • , Ernest S. Neale
    • , Annie Y. Yao
    •  & Ronald C. Desrosiers
  3. Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544, USA

    • Markus von Schaewen
    •  & Alexander Ploss
  4. Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA

    • Kevin G. Haworth
    •  & Paula M. Cannon
  5. Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA

    • Julie M. Decker
    •  & Beatrice H. Hahn
  6. Immunathon Inc., Cambridge, Massachusetts 02141, USA

    • Michael D. Alpert
  7. Department of Pathology, University of Miami Miller School of Medicine, Miami, Florida 33136, USA

    • Sebastian P. Fuchs
    • , Jose M. Martinez-Navio
    •  & Ronald C. Desrosiers
  8. Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA

    • Hugo Mouquet
    •  & Michel C. Nussenzweig
  9. Department of Immunology, Institut Pasteur, Paris, 75015, France

    • Hugo Mouquet
  10. Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA

    • Jason Gorman
    • , Baoshan Zhang
    •  & Peter D. Kwong
  11. Department of Immunology and Microbial Science, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California 92037, USA

    • Pascal Poignard
    •  & Dennis R. Burton
  12. Howard Hughes Medical Institute, New York, New York 10065, USA

    • Michel C. Nussenzweig
  13. Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts 02139, USA

    • Dennis R. Burton
  14. AIDS and Cancer Virus Program, Leidos Biomedical Research, Incorporated, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, USA

    • Michael Piatak
    •  & Jeffrey D. Lifson
  15. Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA

    • Guangping Gao
  16. Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin 53711, USA

    • David T. Evans
  17. Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA

    • Michael S. Seaman


  1. Search for Matthew R. Gardner in:

  2. Search for Lisa M. Kattenhorn in:

  3. Search for Hema R. Kondur in:

  4. Search for Markus von Schaewen in:

  5. Search for Tatyana Dorfman in:

  6. Search for Jessica J. Chiang in:

  7. Search for Kevin G. Haworth in:

  8. Search for Julie M. Decker in:

  9. Search for Michael D. Alpert in:

  10. Search for Charles C. Bailey in:

  11. Search for Ernest S. Neale in:

  12. Search for Christoph H. Fellinger in:

  13. Search for Vinita R. Joshi in:

  14. Search for Sebastian P. Fuchs in:

  15. Search for Jose M. Martinez-Navio in:

  16. Search for Brian D. Quinlan in:

  17. Search for Annie Y. Yao in:

  18. Search for Hugo Mouquet in:

  19. Search for Jason Gorman in:

  20. Search for Baoshan Zhang in:

  21. Search for Pascal Poignard in:

  22. Search for Michel C. Nussenzweig in:

  23. Search for Dennis R. Burton in:

  24. Search for Peter D. Kwong in:

  25. Search for Michael Piatak in:

  26. Search for Jeffrey D. Lifson in:

  27. Search for Guangping Gao in:

  28. Search for Ronald C. Desrosiers in:

  29. Search for David T. Evans in:

  30. Search for Beatrice H. Hahn in:

  31. Search for Alexander Ploss in:

  32. Search for Paula M. Cannon in:

  33. Search for Michael S. Seaman in:

  34. Search for Michael Farzan in:


M.R.G. and L.M.K. contributed equally to this work. M.R.G., L.M.K., H.R.K., M.V.S., T.D., J.J.C., M.D.A., M.P., J.D.L., R.C.D., D.T.E., B.H.H., P.M.C., M.S.S., A.P. and M.F. designed experiments. M.R.G., L.M.K., H.R.K., M.V.S., T.D., J.J.C., K.G.H., J.M.D., M.D.A., C.C.B., C.H.F., V.R.J., B.D.Q. and A.Y.Y. performed experiments. L.M.K. conducted all non-human primate studies. J.G. and P.D.K. assisted with modelling. J.M.M.-N., H.M., B.Z., P.P., M.S.S., M.C.N. and D.R.B. contributed advice and critical reagents. M.F. conceived the study and, with important assistance from M.R.G. and L.M.K., wrote the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Michael Farzan.

Extended data

About this article

Publication history






Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.